Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update

Clearmind Medicine Inc. (NASDAQ:CMND) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 92,700 shares, a decrease of 59.8% from the February 29th total of 230,700 shares. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is presently 0.1 days. Currently, 3.2% of the company’s stock are short sold.

Institutional Trading of Clearmind Medicine

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC acquired a new stake in Clearmind Medicine in the first quarter valued at about $59,000. Warberg Asset Management LLC acquired a new stake in Clearmind Medicine in the third quarter valued at about $35,000. Finally, Walleye Capital LLC acquired a new stake in Clearmind Medicine in the third quarter valued at about $62,000. 96.05% of the stock is owned by institutional investors and hedge funds.

Clearmind Medicine Stock Performance

Shares of Clearmind Medicine stock traded down $0.02 on Friday, reaching $1.15. 38,618 shares of the company were exchanged, compared to its average volume of 346,930. Clearmind Medicine has a one year low of $0.92 and a one year high of $50.10. The company has a 50-day moving average of $1.42 and a 200 day moving average of $3.12. The company has a current ratio of 1.96, a quick ratio of 1.96 and a debt-to-equity ratio of 0.01.

Clearmind Medicine (NASDAQ:CMND) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.90) EPS for the quarter.

About Clearmind Medicine

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.